DiseaseSignal
Breakthrough bottleneck

For an unsolved rare-disease case, when does reinterpretation add more value than new sequencing?

Recent cohorts favored systematic reinterpretation, while PHEX case reports show that unsolved disease can also require genome, RNA, or targeted structural assays matched to the hidden variant class.

Human diagnosticMixedTracked since Jul 23, 2026Updated Jul 26, 2026

Reanalysis produced new diagnoses in two cohorts, while three PHEX reports complicate the sequencing-versus-reanalysis framing by exposing transcript and structural-insertion blind spots that required orthogonal assays.

Who encounters this friction
Clinical geneticists, diagnostic laboratories, rare-disease researchers, and affected families.
Evidence so far

Reanalysis identified causative variants in 17 of 101 previously unsolved neuromuscular families. In a separate 20-family pediatric cohort, reported diagnostic variants were also recoverable by research short-read sequencing or reinterpretation. Two PHEX reports connected deep-intronic genome candidates to abnormal RNA splicing, and a third resolved a partial LINE-1 insertion with targeted long-range PCR and Sanger sequencing after routine genome calls had not described it.

Why it matters

Families and laboratories face a real sequencing-versus-reanalysis decision. Better comparative evidence could prevent both missed diagnoses and unnecessary testing.

Missing proof

Larger comparative cohorts, standardized reanalysis intervals, cost and turnaround comparisons, variant-class-specific yield, diverse populations with equivalent analytic pipelines, and prospective rules for escalating from sequence review to RNA or targeted structural assays.

Next decisive test

Prospectively compare updated short-read reinterpretation, genome review, transcript testing, and targeted or long-read structural analysis in the same unsolved cases, using locked pipelines and variant-class, cost, turnaround, and diagnostic-yield endpoints.

Evidence movement

What changed

Newest evidence first. Labels describe the bottleneck, not treatment effectiveness.

  1. Mixed

    Three PHEX reports complicated the reanalysis-versus-new-sequencing bottleneck by showing that deep-intronic splice effects and a structural insertion required RNA or targeted DNA assays after initial sequence-level detection.

    3 linked primary sources

  2. Mixed

    Two diagnostic cohorts favored renewed interpretation of existing data in their reported cases, without ruling out long-read value for other variant classes or populations.

    2 linked primary sources

Evidence trail

Primary studies and briefings

5 primary sources. Every interpretation remains bounded by the linked evidence.

Genetics

Read the DiseaseSignal evidence briefing

  1. Systematic reanalysis in 101 neuromuscular disorder families PMID 42474733 · DOI 10.1007/s00415-026-13994-9
  2. Clinical genome reanalysis using long-read sequencing PMID 42050932 · DOI 10.1016/j.xhgg.2026.100620

Genetics

Read the DiseaseSignal evidence briefing

  1. Deep intronic PHEX variant resolved by genome and targeted RNA sequencing PMID 42494860 · DOI 10.3389/fendo.2026.1847219
  2. Deep intronic PHEX variant in a Finnish family PMID 39877728 · DOI 10.1093/jbmrpl/ziae169
  3. Partial LINE-1 insertion in PHEX PMID 42079344 · DOI 10.1155/humu/3376327
How to read evidence movement

EmergingA newly supported problem worth tracking.

StrengtheningAdditional evidence reinforces the bottleneck framing.

MixedEvidence supports some parts while important conflicts or limits remain.

UnchangedNew evidence does not materially change the open problem.

WeakenedNew evidence reduces confidence that this is the central bottleneck.

These labels track an unresolved research problem. They do not score a treatment or predict benefit for an individual.